An analysis of data on Sanofi’s dengue vaccine, which has been given to more than 800,000 school children in the Philippines, confirms it increases the risk of hospitalization and severe dengue in those who had never previously been infected with the mosquito-borne virus.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,